Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com

NEW YORK, Aug. 3, 2015 /CNW/ -- Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP), today announced that Immune's CEO, Dr. Daniel Teper, will present live at VirtualInvestorConferences.com on August 6, 2015.

DATE:  Thursday, August 6, 2015
TIME:   11:30AM EDT
LINK:    http://tinyurl.com/aug6-pre-imnp

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates. Learn more about the event: http://VirtualInvestorConferences.com

Recent Company Highlights

  • Immune Pharmaceuticals secures Funding of up to $21.5 Million from Institutional Investors
  • Immune Pharmaceuticals Initiates Phase II Clinical Trials with Bertilimumab in Ulcerative Colitis and Bullous Pemphigoid
  • Immune Expands Immuno-Dermatology Development Portfolio with Topical Nano-Formulated Cyclosporine A
  • Immune Pharmaceuticals Signs License & Research Agreement for AmiKet™ Nano

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Expanding its portfolio in immuno-dermatology, topical nano-formulated Cyclosporine A (CsA) for the treatment of psoriasis and atopic dermatitis. Immune's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a topical neuropathic pain drug candidate.

For more information, visit Immune's website at www.immunepharmaceuticals.com

About VirtualInvestorConferences.com
VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

SOURCE Immune Pharmaceuticals, Inc.

For further information: Christine J. Petraglia, Director, Corporate Communications and Investor Relations, Immune Pharmaceuticals, Inc., +1.646.440.9310, Christine.petraglia@immunepharma.com; VirtualInvestorConferences.com: Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, bradley.smith@prnewswire.com, http://www.immunepharmaceuticals.com

Organization Profile

Immune Pharmaceuticals, Inc.

More on this organization

Virtual Investor Conferences

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890